Promising clinical trial results published on 44 patients with small lung nodules that were previously considered hard to reach with conventional tools.
Gigi Gelvosa is an OR nurse at Seton Brain & Spine in Austin, Texas. She’s not just any OR nurse — she’s the nurse of Dr. Ziu, BrainPath user. Recently, though, she became the patient of Dr. Ziu after suffering a hemorrhagic stroke…and was the recipient of a BrainPath surgery. Watch this TV 7 news story that shares her story or survival. Dr. Ziu says THIS tube is not just any tube and without it, his nurse’s hemorrhage would have been inoperable.
Early in 2016, private capital markets have tightened. There are no shortage of predictions that valuation multiples will drop, round sizes will shrink and down rounds will steal headlines. Many believe that investors will raise the bar (on new investments and follow-on checks) and be unwilling to stomach previously tolerated burn rates. So, what does this mean for you, the entrepreneur contemplating a 2016 capital raise? In particular, we’ll focus on how much you should raise and whether that answer is different today than it was a year ago.
Partnership combines location marketing with transparency to drive patient acquisition at scale.
NEOX® Wound Allograft accessible to more than 4.4 Million additional medicare lives.
Continued growth reflects new momentum for comprehensive care team collaboration tools in the industry ranging from hospitals to physician offices to other ambulatory care settings
A new clinical study was recently published and was focused on utilizing Veran’s SPiN Thoracic Navigation System and SPiNPerc, a navigated percutaneous approach to biopsy peripheral lung nodules, to biopsy suspicious peripheral lung nodules. The study was completed by a team of researchers at the Johns Hopkins University School of Medicine and was recently published in the Journal of Thoracic Disease.
Amniox highlights study showing more than 87% of patients with diabetic foot ulcers achieve healing when treated with NEOX® Wound Allograft.
The company has 21 facilities in Arkansas, Mississippi and Tennessee and plans to use the $35 million debt and equity investment from Crestline Investors to develop new facilities and make an acquisition.
Leading call tracking and attribution technology provider expands C-suite with addition of seasoned marketing executive to support exponential growth.